DreamCIS, Inc. (KOSDAQ:223250)
South Korea · Delayed Price · Currency is KRW 4,645.00
-355.00 (-7.10%)
At close: Apr 2, 2026
DreamCIS Revenue
In the year 2025, DreamCIS had annual revenue of 66.63B KRW with 13.60% growth. DreamCIS had revenue of 19.34B in the quarter ending December 31, 2025, with 30.91% growth.
Revenue
66.63B
Revenue Growth
+13.60%
P/S Ratio
1.71
Revenue / Employee
170.85M
Employees
390
Market Cap
114.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 66.63B | 7.98B | 13.60% |
| Dec 31, 2024 | 58.65B | 10.81B | 22.59% |
| Dec 31, 2023 | 47.84B | 8.97B | 23.08% |
| Dec 31, 2022 | 38.87B | 12.72B | 48.64% |
| Dec 31, 2021 | 26.15B | 2.66B | 11.34% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HLB bioStep | 74.05B |
| C&R Research | 64.98B |
| DT&CRO CO. | 47.75B |
| WOOJUNG BIO | 37.59B |
| BioInfra | 23.15B |
| P&K Skin Research Center | 22.78B |
| Penetrium Bioscience | 9.74B |
| Curachem | 6.02B |